Reunion is a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions that serve as safe, fast-acting, short duration therapies for underserved mental health disorders, beginning with postpartum depression (PPD), adjustment disorder (AjD) and generalized anxiety disorder (GAD). We envision a day when depression and other mental health conditions aren’t just disorders that can be managed, but instead are curable. We relentlessly pursue the development of safer therapeutics that provide durable antidepressive effects for the millions of people whose needs are not met by the current standard of care.
RECENT NEWS AND MEDIA COVERAGE
February 23, 2026: U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
February 19, 2026: Reunion Neuroscience today announced its participation in the following upcoming conferences:
January 20, 2026: Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
Leading with Bold Science
Our approach builds upon the decades of psychedelic research that reveals promising results across various mental health conditions. Our lead clinical-stage drug candidate, RE104, is a potential best-in-class, short duration, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. RE104 targets the serotonin 2A receptor (5HT2AR), which is the recognized target for the antidepressant effects of psychedelic compounds.
Experience, Meet Innovation
Reunion’s team consists of industry entrepreneurs and scientific leaders with deep experience in every aspect of neuroscience pharmaceutical drug development. We’re blazing the path to create a transformative new generation of therapeutics to create a world where mental and emotional wellbeing is the baseline.
